Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Via News Knowledge File

Micron Technology Inc

organization80% conf.·synced Oct 15, 2026

Memory and storage solutions manufacturer

60
sourced metrics
907
relationships
20
stated objectives
5
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price
914.13USD
Oct 14, 2026reference only
Market Cap
1032412161124USD
Oct 14, 2026reference only
Price 52 Week Low
191.94USD
Oct 14, 2026reference only
Stock Return Ytd
189.8%
Oct 14, 2026reference only
Price 52 Week High
1213.56USD
Oct 14, 2026reference only
Shares Outstanding
1129393151.0shares
Jun 17, 2026reference only
Cash
24995000000.0USD
May 28, 2026reference only
Cost Of Revenue
6400000000.0USD
May 28, 2026reference only
Stockholders Equity
100724000000.0USD
May 28, 2026reference only
Revenue
41456000000.0USD
May 28, 2026reference only
Net Income
28243000000.0USD
May 28, 2026reference only
Gross Profit
35056000000.0USD
May 28, 2026reference only
Total Liabilities
33388000000.0USD
May 28, 2026reference only
Operating Income
33318000000.0USD
May 28, 2026reference only
Total Assets
134112000000.0USD
May 28, 2026reference only
Rd Expense
1316000000.0USD
May 28, 2026reference only
Eps
24.67USD_per_share
May 28, 2026reference only
Capex
5389000000.0USD
Nov 27, 2025reference only

Stated objectives

Achieve adjusted EPS of around $19.15 in Q3

source
target: 19.15 USD per share stated

Grow HBM market to $100 billion total addressable market

source
target: 100 billion USD by 2028-01-01 00:00:00stated

Begin production at Singapore HBM fab

source
by 2027-01-01 00:00:00stated

Begin DRAM production at retooled PSMC Taiwan fab

source
stated

Reach full production at Onondaga County, New York DRAM megafab complex

source
by 2030-01-01 00:00:00stated

Micron guided to Q1 FY2025 revenue between $12.2bn and $12.8bn

source
target: 12.2–12.8 billion USD stated

Micron guided to Q1 FY2025 adjusted EPS between $3.60 and $3.90

source
target: 3.60–3.90 USD EPS stated

$20 billion capital investment for fiscal 2026 including New York megafab and Idaho facility

source
target: 20 billion USD stated

Strategic focus on high-growth data center segments following exit from consumer products

source
stated

Complete first semiconductor fabrication facility outside Syracuse

source
by 2030-12-31 00:00:00stated

Relationship graph · 907 connections

Competes with
208
Supplies to
183
Covered by
164
Developed by
86
Invested in
50
Customer of
44
located in
31
Employs
30
has patent dispute with
Netlist

Via News coverage

Micron's Capex Nearly Doubled to $15.9 Billion as Analysts Cheer the AI Buildout, While European Exposure Runs Through Chips, Not Rules
October 9, 2026
Europe's Small Seat at the AI Chip Boom: Micron's Spending Doubled, ASML Rallied, and Grenoble's Kalray Signed With Bull
October 8, 2026
Micron's Spending Tripled in Two Years as the AI Buildout Reached Memory Chips, While Weaker Corners of the Market Were Left Behind
October 1, 2026
As Wall Street Sells the AI Chip Rally, Europe's Networking Deals Show the Buildout Hasn't Stopped
August 16, 2026
Amid a Global AI-Chip Selloff, a French Networking Deal Argues the Boom Is Repricing, Not Ending
August 15, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com